Pacira Pharmaceuticals Inc (NASDAQ:PCRX)’s share price dropped 16.5% during trading on Monday . The company traded as low as $29.35 and last traded at $30.15. Approximately 3,918,200 shares traded hands during mid-day trading, an increase of 251% from the average daily volume of 1,114,781 shares. The stock had previously closed at $36.10.
PCRX has been the subject of a number of recent research reports. Jefferies Group dropped their price objective on shares of Pacira Pharmaceuticals to $52.00 and set a “buy” rating for the company in a research note on Thursday, November 9th. ValuEngine raised shares of Pacira Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, January 10th. Canaccord Genuity set a $42.00 target price on shares of Pacira Pharmaceuticals and gave the stock a “hold” rating in a report on Wednesday, November 29th. Piper Jaffray Companies restated a “buy” rating and issued a $55.00 target price on shares of Pacira Pharmaceuticals in a report on Friday, October 27th. Finally, Wedbush restated an “outperform” rating and issued a $87.00 target price on shares of Pacira Pharmaceuticals in a report on Wednesday, October 25th. Four equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $46.53.
The firm has a market capitalization of $1,220.00, a price-to-earnings ratio of -23.02 and a beta of 1.88. The company has a debt-to-equity ratio of 1.03, a quick ratio of 6.24 and a current ratio of 6.99.
In related news, CEO David M. Stack sold 28,885 shares of Pacira Pharmaceuticals stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $40.19, for a total transaction of $1,160,888.15. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 6.60% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. MetLife Investment Advisors LLC bought a new stake in Pacira Pharmaceuticals during the 4th quarter valued at about $845,000. Redmile Group LLC bought a new stake in Pacira Pharmaceuticals during the 4th quarter valued at about $237,000. Element Capital Management LLC bought a new stake in Pacira Pharmaceuticals during the 4th quarter valued at about $6,144,000. Macquarie Group Ltd. lifted its holdings in Pacira Pharmaceuticals by 9.7% during the 4th quarter. Macquarie Group Ltd. now owns 1,266,414 shares of the company’s stock valued at $57,812,000 after buying an additional 111,869 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in Pacira Pharmaceuticals during the 4th quarter valued at about $501,000.
ILLEGAL ACTIVITY NOTICE: “Pacira Pharmaceuticals (PCRX) Shares Down 16.5%” was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://ledgergazette.com/2018/02/19/pacira-pharmaceuticals-pcrx-shares-down-16-5.html.
Pacira Pharmaceuticals Company Profile
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.